The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Estimated NAV at 31 October 2021

12 Nov 2021 07:00

RNS Number : 1181S
Standard Life Private Eqty Trst PLC
12 November 2021
 

Standard Life Private Equity Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

12 November 2021

Standard Life Private Equity Trust plc ("SLPET" or "the Company") announces its estimated net asset value ("NAV") at 31 October 2021

· Estimated NAV at 31 October 2021 was 613.0 pence per share (estimated NAV at 30 September 2021 was 627.1 pence per share)

· Third interim dividend of 3.4 pence per share paid on 29 October 2021

· SLPET paid £20.6 million of drawdowns and received £19.6 million of distributions during the month of October

· One new primary commitment and two new co-investments completed

· Outstanding commitments of £544.7 million at 31 October 2021

SLPET's valuation policy for private equity funds and co-investments is based on the latest valuations reported by the managers of the funds and co-investments in which the Company has interests. In the case of SLPET's valuation at 31 October 2021, excluding new investments, 100.0% by value of the portfolio valuations were dated 30 June 2021.

 

Estimated NAV

At 31 October 2021, SLPET's estimated NAV was 613.0 pence per share (estimated net assets £942.5 million), representing a 2.2% per share decrease from the estimated NAV at 30 September 2021 of 627.1 pence per share (estimated net assets £964.2 million). The 14.1 pence decrease in NAV per share reflected losses arising primarily from a 1.8% depreciation in the euro versus sterling during October, in addition to the third interim dividend payment of 3.4 pence per share on 29 October 2021. The cash cost of the third interim dividend was £5.2 million.

 

Drawdowns and distributions

SLPET paid £20.6 million of drawdowns and received £19.6 million of distributions during the month of October. The distributions received generated realised gains and income of £12.8 million. Including secondary sales, total net inflows from investment activity during October amounted to £14.5 million.

 

Investment activity

A new primary commitment of €20.0 million was made to Capiton VI in October.

A £4.2 million co-investment was made into SportPursuit, a flash sale e-commerce business which sells clearance stock from leading sports and outdoor brands. The co-investment was made alongside sponsor bd-capital Partners.

A €7.5 million co-investment was made into SuanFarma, a manufacturer, CDMO and distributor of active pharmaceutical and nutraceutical ingredients. The co-investment was made alongside sponsor ArchiMed SaS.

The Company has also sold its interest in Equistone Partners Europe Fund VI for a consideration of €18.2 million. This fund interest had outstanding commitments of €14.2 million prior to the date of sale.

 

Commitments

The Company had £544.7 million of outstanding commitments at 31 October 2021. The Manager believes that around £42.2 million of the Company's existing outstanding commitments are unlikely to be drawn.

 

Balance sheet and credit facility

The Company had cash and cash equivalents of £37.6 million at 31 October 2021. In addition, the Company has an undrawn £200.0 million syndicated revolving credit facility, provided by Citi, Societe Generale and State Street Bank International, that expires in December 2024.

 

Update from the Manager

The latest update from the Manager is available within the Latest News section of the Company website; www.slpet.co.uk.

 

Future announcements

The Company is expecting to announce its estimated NAV at 30 November 2021 on or around 14 December 2021. 

Additional detail about SLPET's NAV and investment diversification can be found on SLPET's website. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website is incorporated into, or forms part of, this announcement.

 

For further information please contact Alan Gauld at SL Capital Partners LLP (0131 528 4424)

Note:-

Standard Life Private Equity Trust plc is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010. The Board of Standard Life Private Equity Trust plc is independent of abrdn plc and Phoenix Group Holdings.

Valuation Methodology

Unquoted investments are stated at the directors' estimate of fair value and follow the recommendations of EVCA and BVCA. The estimate of fair value is normally the latest valuation placed on an investment by its manager at the balance sheet date. The valuation policies used by the manager in undertaking that valuation will generally be in line with the joint publication from EVCA and BVCA, 'International Private Equity and Venture Capital Valuation guidelines'. Where formal valuations are not completed at the balance sheet date, the last available valuation from the manager is adjusted for any subsequent cashflows occurring between the valuation date and the balance sheet date. The Company's Manager may further adjust such valuations to reflect any changes in circumstances from the last manager's formal valuation date to arrive at the estimate of fair value.

The Company intends to release regular estimated NAV updates around ten business days after each month end, while continuing to issue quarterly updates. A breakdown of SLPET's portfolio can be obtained in the latest monthly factsheet, which is published on SLPET's website at:

www.slpet.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVBBBBTMTABBBB
Date   Source Headline
17th Jan 20207:00 amRNSDoc re. Annual Report
15th Jan 20207:00 amRNSMonth End Net Asset Value(s)
14th Jan 20204:18 pmRNSDirector/PDMR Shareholding
9th Jan 20207:00 amRNSAnnual Financial Report
6th Jan 202011:31 amRNSQuarterly Disclosure
13th Dec 20197:00 amRNSMonth End Net Asset Value(s)
12th Dec 20197:00 amRNSFourth Quarter Dividend Declaration
14th Nov 20197:00 amRNSMonth end Net Asset Value(s)
12th Nov 20194:22 pmRNSDirector/PDMR Shareholding
1st Nov 20192:45 pmRNSDirector/PDMR Shareholding
14th Oct 201911:00 amRNSMonth End Net Asset Value(s)
3rd Oct 201911:05 amRNSQuarterly Disclosure
27th Sep 20192:50 pmRNSEstimated Net Asset Value at 31 August 2019
27th Sep 20192:44 pmRNSQuarterly Trading Statement
12th Sep 20197:00 amRNSDeclaration of Third Quarter Dividend
29th Aug 20197:05 amRNSCompany Secretary Change
14th Aug 20192:24 pmRNSDirector/PDMR Shareholding
14th Aug 20197:00 amRNSEstimated Net Asset Value at 31 July 2019
5th Aug 201911:10 amRNSDirector Declaration
30th Jul 201910:53 amRNSDirector/PDMR Shareholding
12th Jul 20197:00 amRNSEstimated Net Asset Value at 30 June 2019
2nd Jul 20191:11 pmRNSQuarterly Disclosure
19th Jun 20197:06 amRNSEstimated Net Asset Value at 31 May 2019
19th Jun 20197:00 amRNSHalf-year Report
13th Jun 20197:00 amRNSDividend Declaration
29th May 201911:30 amRNSUpdate research from QuotedData
15th May 20197:00 amRNSEstimated Net Asset Value as at 30 April 2019
2nd May 201911:02 amRNSDirector/PDMR Shareholding
12th Apr 20197:00 amRNSEstimated Net Asset Value at 31 March 2019
2nd Apr 20193:55 pmRNSQuarterly Disclosure
1st Apr 201910:08 amRNSChange of Depositary
25th Mar 20197:00 amRNSEstimated net asset value as at 28 February 2019
25th Mar 20197:00 amRNSQuarterly Trading Statement
14th Mar 201911:31 amRNSEdison issues review on Standard Life Private
14th Mar 20197:00 amRNSDividend Declaration
14th Feb 20197:00 amRNSEstimated Net Asset Value at 31 January 2019
29th Jan 20194:27 pmRNSDirector/PDMR Shareholding
22nd Jan 20192:17 pmRNSResult of AGM
15th Jan 20197:00 amRNSEstimated Net Asset Value at 31 December 2018
3rd Jan 20192:17 pmRNSQuarterly Disclosure
31st Dec 201811:18 amRNSDividend Declaration
27th Dec 201811:03 amRNSDirector/PDMR Shareholding
18th Dec 201811:27 amRNS2018 Annual Report and AGM
14th Dec 20187:00 amRNSEstimated Net Asset Value at 30 November 2018
12th Dec 20187:00 amRNSAnnual Financial Report
7th Dec 20184:05 pmRNSDirectorate Change
14th Nov 20187:00 amRNSEstimated Net Asset Value at 31 October 2018
6th Nov 20183:27 pmRNSDirector/PDMR Shareholding
2nd Nov 201812:02 pmRNSDirector/PDMR Shareholding
12th Oct 20187:00 amRNSEstimated Net Asset Value at 30 September 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.